Nightfood Holdings Subsidiary TechForce Deploys Autonomous Lab Robot in Pharmaceutical Automation Milestone
TechForce Robotics successfully deployed LIM-E, an autonomous laboratory robot, marking its first expansion into pharmaceutical automation and validating its AI platform's adaptability beyond hospitality.
Nightfood Holdings Inc. (OTCQB: NGTF) announced that its subsidiary, TechForce Robotics, has completed Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the initial deployment of LIM-E, an autonomous laboratory support robot. This deployment marks TechForce’s first expansion into pharmaceutical and laboratory automation and validates the adaptability of its AI-enhanced robotics platform beyond hospitality and service-industry applications into life sciences and pharmaceutical environments.
TechForce said the deployment completed the initial operational goals established under the companies’ April 2026 collaboration agreement and will provide operational data and workflow insights to support future automation initiatives. The companies plan to continue evaluating opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows and other automation applications, while Nightfood views healthcare, life sciences and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service platform.
This milestone is important because it demonstrates the cross-industry potential of TechForce's robotics platform, which was previously focused on hospitality and foodservice. By successfully deploying LIM-E in a pharmaceutical setting, TechForce opens up new revenue streams and addresses a critical need for automation in laboratory environments, where precision and consistency are paramount. The pharmaceutical industry is increasingly turning to automation to improve efficiency, reduce errors, and accelerate research and development processes.
For Oncotelic Therapeutics, a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, the collaboration with TechForce could streamline its laboratory operations, potentially speeding up drug development timelines. The partnership also reflects a broader trend of convergence between AI-enhanced robotics and life sciences, as companies seek to leverage technology to gain competitive advantages.
Nightfood Holdings, through its TechForce Robotics platform, is positioning itself to capitalize on the growing demand for automation in healthcare and pharmaceutical manufacturing. The company’s Robotics-as-a-Service (RaaS) model offers clients flexible access to advanced robotic systems without the need for large upfront capital investments, making automation more accessible to mid-sized and smaller enterprises.
For more information, see the full press release at https://ibn.fm/RFkfL and visit Nightfood Holdings at www.nightfoodholdings.com.